Introduction
Tetrazoles are heterocyclic, five-membered rings containing four nitrogens and one carbon atom (CN4H2) [1] . Presence of four nitrogen atoms makes them acidic. They undergo electrophilic as well as nucleophilic substitution [2] . They can act as pharmacophore for the carboxylate group, which increases their utility. Tetrazoles are Angiotensin II blockers as in Losartan and Candesartan [1, 3, 4] . Tetrazoles and its derivatives show most promising biological activities like antibacterial, antiviral, antifungal, anticonvulsant, anticancer, hypoglycemic, antinociceptive and ulcerogenicity index [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . They are cyclooxygenase inhibitors and therefore exhibit analgesic, anti-inflammatory activities [4, 17] .
It was observed that several highly mutagenic and carcinogenic quinoxalines have been found in heated meat and fried fish. Some of the quinoxaline derivatives have been identified as mild hypo glycaemic agents and used for treating pain, epilepsy and other neurodegenerative disorders. Due to DNA binding properties of quinoxalines, they show highest activity against the herpes virus.
They are part of well-known antibiotics such as levomycin, echinomycin, and actinoleutin that are known to inhibit growth of gram positive bacteria. Quinoxalines show various biological activities such as anti-viral, anti-depressant and as kinase inhibitors. They are active against transplantable tumors.
Fusion of tetrazole with quinoxalinesis considered as planar acidic heterocyclic analogue of carboxylic function, which has the ability to increase potency and enhance bioavailability [18, 19] .
1,3,4-Oxadiazole is a neutral aromatic molecule which is thermally stable [20] . Quinoxalines containing 1,3,4-oxadiazole have been shown to possess a broad biological activity spectrum including antibacterial, antifungal, antiviral, anticancer, antihypertensive, anticonvulsant and anti-diabetic properties [20, 21] .
Ar: 5a 5Ph; 5b 3F-Ph; 5c 4F-Ph; 5d 2OH-Ph; 5e 3OH-Ph; 5f 4-OCH3-Ph; 5g 2OCH3-Ph; 5h 3-OCH3-Ph Ar: 6a 5Ph; 6b 3F-Ph; 6c 4F-Ph; 6d 2OH-Ph; 6e 3OH-Ph; 6f 4-OCH3-Ph; 6g 2OCH3-Ph; 6h 3-OCH3-Ph Reagents and conditions: a) C2H5OH, ethyl chloroacetate, dry K2CO3, reflux, 80 °C, overnight; b) Ethanol, NH2NH2, reflux, 80-90 °C, 5 hrs; c) RCHO, DMF, glacial acetic acid, reflux, 3 hr; d) Chloramine-T, ethanol, reflux, 80-90 °C, 5 hrs.; e) Aryl tetrazole, acetone, anhydrous K2CO3.
Scheme 1
Quinoxalines when fused with oxadiazole moiety was also identified as a Selective inhibitor of Guanylyl Cyclase (SGC) and important heme-site inhibitors for nitric oxide donor bioactivation. Moreover, the combined presence of quinoxaline and 1,3 4-oxadiazole in one frame are expected to show promising anti-inflammatory, analgesic and anticonvulsant activities.
Taking into account the importance of quinoxalines, tetrazoles and 1,3,4-oxadiazoles to both medicinal and heterocyclic chemistry, the following 2-((5-aryl-1,3,4-oxadiazol-2-yl)methoxy)-3-methyl quinoxaline and 3-methyl quinoxalin-2-yl-2-(5-aryl-2H-tetrazol-2-yl)acetate are synthesized. The structures of the synthesized compounds were confirmed by IR, 1 H NMR, 13 C NMR and Mass spectral data. All the synthesized derivatives were tested in vitro for their antibacterial activity.
Experimental

Instrumentations and reagents
All chemicals and reagents were of analytical grade and purchased from Merck. Solvents were used in purified form. For thin-layer chromatography (TLC) E. Merck AL silica gel 60F254 plates were used and spots were visualized under UV light. Melting points were determined by using Mel-temp apparatus and are uncorrected. IR spectra were recorded on Perkin Elmer (FT-IR) spectrometer. Only intense peaks are diagnosed and reported. 1 H NMR spectra were recorded using Varian NMR-400 MHz instrument. All the chemical shifts were reported in δ (ppm) using TMS as an internal standard. Signals are indicated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad); and coupling constants in Hz. Mass spectra were recorded with a PESciex model API 3000 mass spectrometer. All the reactions were carried out under the atmosphere of an inert gas, argon.
Synthesis
Synthesis of ethyl-2-(2-methylquinoxalin-3-yloxy) acetate (2)
3-Methyl quinoxalin-2-ol (0.01 mmol) was dissolved in ethanol (15 mL). To this solution ethylchloro acetate (0.01 mmol) and dry potassium carbonate (3 g) were added and refluxed at 80 °C for overnight. After the completion of reaction (monitored by TLC), the mixture was poured into ice cold water and filtered to separate the solid. The product was recrystallized from methanol (Scheme 1 
Synthesis of 2-(2-methylquinoxalin-3-yloxy)aceto hydrazide (3)
To a solution of ethyl 2-(2-methylquinoxalin-3-yloxy) acetate (2) (0.01 mmol) in ethanol, was added hydrazine hydrate (99%, 20 mL) and refluxed for 5 h on a water bath at 80-90 °C. The reaction mixture was cooled and poured into crushed ice with stirring and kept aside for 30min for the precipitate to settle. The resultant precipitate was filtered, washed with water, dried and recrystallized from ethanol 
MS (EI, m/z (%)): 337 (M+H).
2-((5-(2-Hydroxy phenyl)-1,3,4-oxadiazol-2-yl)methoxy)-3-methyl quinoxaline
. MS (EI, m/z (%)): 335 (M+H).
2-((5-(4-Methoxy phenyl)-1,3,4-oxadiazol-2-yl)methoxy)-3-methyl quinoxaline
2-((5-(3-Methoxy phenyl)-1,3,4-oxadiazol-2-yl)methoxy)-3-methyl quinoxaline
Synthesis of 3-methylquinoxalin-2-yl-2-(5-aryl-2H-tetrazol-2-yl)acetate (6a-h)
A round-bottom flask equipped with a magnetic stirrer was charged with aryltetrazole (0.14 mmol) and acetone (25 mL). The suspension was cooled to 0 °C before adding anhydrous potassium carbonate. After stirring for 30 minutes at 0 °C, 3-methylquinoxalin-2-yl 2-bromoacetate (0.16 mmol) was added to the opaque mixture. The reaction was stirred for 16 h while slowly warming to room temperature. The mixture was filtered and thoroughly washed with additional acetone. The clear filtrate was concentrated under reduced pressure to give solid (Scheme 1). 
3-Methylquinoxalin-2-yl-2-(5-phenyl-2H-tetrazol-2-yl
Results and discussions
Taking into account the importance of quinoxalines, tetrazoles and 1,3,4-oxadiazoles to both medicinal and heterocyclic chemistry, 2-((5-aryl-1,3,4-oxadiazol-2-yl) methoxy)-3-methyl quinoxaline and 3-methylquinoxalin-2-yl-2-(5-aryl-2H-tetrazol-2-yl)acetate derivatives are synthesized from N'-Arylidene-2- ((3-methylquinoxalin-2-yl)oxy) aceto hydrazide. The structures of the synthesized compounds were confirmed by 1 H NMR, 13 C NMR and Mass spectral data. They have been screened for their antibacterial activity against four pathogenic strains.
The screening results of antibacterial activity of 1,3,4-oxadiazole and tetrazole derivatives 5a-f and 6a-f are summarized in Table 1 . Compounds 5c, 6d and 6g show moderate activity in the range of 20-24 mm against S. aureus. Compounds 5f and 6h exhibit moderate activity against B. subtilis. Compounds 5c and 6f against E. coli and compounds 5c and 6h against P. aeruginosa. Compounds 5f, 6d and 6g exhibit excellent activity in the range of 25-28 mm against P. aeruginosa. Compound 6e shows appreciable activity against B. subtilis.
Conclusion
Herein we reported the synthesis of some new, 2-((5-aryl-1,3,4-oxadiazol-2-yl)methoxy)-3-methyl quinoxaline and 3-methylquinoxalin-2-yl-2-(5-aryl-2H-tetrazol-2-yl)acetate derivatives and recorded their antibacterial activity.
